Royalty Pharma revenue and financials
$56.70Change from previous close: +0.07%Absolute change: +$0.04
In the fiscal year ended December 2025, Royalty Pharma reported revenue of $2.38B (+5.06% year over year). Net income was $770.95M, a net margin of 32.4%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +5.06%
- 2025 vs 2024
- Net income growth
- −10.25%
- 2025 vs 2024
- Net margin
- 32.4%
- 2024: 37.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Total revenue | 2,378 | 2,264 | 2,355 | 2,237 | 2,289 | 2,122 | 1,814 | 1,795 |
| Cost of revenue | -296 | 732 | 561 | 904 | 453 | — | — | — |
| Gross profit | 2,674 | 1,531 | 1,794 | 1,333 | 1,837 | — | — | — |
| Selling, general and administrative | 573 | 237 | 250 | 227 | 183 | — | — | — |
| Research and development | 452 | 2.0 | 52.0 | 177 | 200 | 26.3 | 83.0 | 393 |
| Operating income | 1,560 | 1,292 | 1,492 | 307 | 1,431 | 1,595 | 2,623 | 1,364 |
| EBIT | 1,560 | 1,292 | 1,492 | 923 | 1,431 | — | — | — |
| EBITDA | 1,563 | 1,556 | 1,498 | 929 | 1,454 | — | — | — |
| Interest expense | 308 | 226 | 187 | 188 | 166 | 157 | 269 | 280 |
| Pre-tax income | 1,324 | 1,331 | 1,700 | 230 | 1,241 | — | — | — |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income | 771 | 859 | 1,135 | 42.8 | 620 | 975 | 2,349 | 1,378 |
| Net income to common shareholders | 771 | 859 | 1,135 | 42.8 | 620 | — | — | — |
| Basic EPS | 1.79 | 1.92 | 2.54 | 0.10 | 1.49 | 1.32 | — | — |
| Diluted EPS | 1.78 | 1.91 | 2.53 | 0.10 | 1.49 | 1.32 | — | — |
| Average shares (basic) | 430 | 448 | 448 | 438 | 415 | — | — | — |
| Average shares (diluted) | 564 | 594 | 603 | 438 | 415 | 375 | — | — |
| Dividend per share | 0.88 | 0.84 | 0.80 | 0.76 | 0.68 | — | — | — |